福多司坦联合常规降压药治疗阻塞性睡眠呼吸暂停综合征伴高血压的临床疗效

发布时间：2018-11-06 07:00

【摘要】：目的:观察福多司坦对阻塞性呼吸暂停综合征(OSAS)合并高血压患者患者的临床效果。方法:选取55名正常人群以及120名OSAS合并高血压患者,患者随机均分为治疗组和对照组,治疗组患者除接受常规降压药物治疗处理外,同时给予福多司坦治疗2个月,对照组患者给予安慰剂及常规降压药物处理,观察两组治疗前后的通气指数(AHI),血氧饱和度(miniSpO_2),炎性因子ICAM-1、VCAM-1、P选择素、E选择素、IL-8、TNF-α、HS-CRP变化情况,并将患者的以上指标与正常人群组比较。结果:OSAS合并高血压患者MT、PMV均高于正常人,以及ICAM-1、VCAM-1、P选择素、IL-8、TNF-α、HSCRP等炎症因子均明显高于常人。联合治疗后,治疗组血压得到改善,AHI下降、miniSpO_2升高,ICAM-1、VCAM-1、P选择素、IL-8、TNF-α均显著降低(P0.05)。结论:福多司坦联合常规降压药治疗OSAS合并高血压具有较好的临床效果。
[Abstract]:Objective: to observe the clinical effect of Fudolestan in patients with obstructive apnea syndrome (OSAS) complicated with hypertension. Methods: 55 normal subjects and 120 patients with OSAS complicated with hypertension were randomly divided into treatment group and control group. In addition to routine antihypertensive drugs, the patients in the treatment group were treated with Fodolestan for 2 months. The patients in the control group were treated with placebo and conventional antihypertensive drugs. The ventilation index (miniSpO_2), inflammatory factors ICAM-1,VCAM-1,P selectin, E selectin and IL-8, were observed before and after treatment. The changes of TNF- 伪 and HS-CRP were compared with the normal group. Results: the levels of MT,PMV, ICAM-1,VCAM-1,P selectin, IL-8,TNF- 伪, HSCRP and other inflammatory factors in patients with OSAS complicated with hypertension were significantly higher than those in normal controls. After combined treatment, blood pressure was improved, AHI decreased, miniSpO_2 increased, ICAM-1,VCAM-1,P selectin and IL-8,TNF- 伪 decreased significantly (P0.05). Conclusion: Fudolestan combined with conventional antihypertensive drugs is effective in the treatment of OSAS with hypertension.
【作者单位】：南京医科大学附属江宁医院呼吸内科;江苏省省级机关医院呼吸内科;南京医科大学附属江宁医院心内科;江苏省人民医院呼吸内科;
【基金】：江苏省卫生厅科研项目(编号:YG201502)
【分类号】：R544.1;R766

【相似文献】